[Costs of a guideline-based treatment of patients with chronic hepatitis C in the era of interferon-free treatment].

The treatment of chronic hepatitis C has considerably changed with the introduction of recent direct acting antivirals. These antivirals have sustained virologic response (SVR) rates above 90% as well as reduced toxicity and treatment duration. Therefore, current German guidelines recommend these interferon-free regimens as first-choice treatment. Nevertheless, recent developments were accompanied by a significant increase in treatment costs, which led to extensive discussions on reasonable pharmaceutical prices. The aim of the current study was to analyze the average treatment costs and costs per patient cured for guideline treatment recommendations. Analyses were stratified according to genotype, treatment status (naive/experienced), and presence/absence of cirrhosis. Costs were separated in (1.) basic diagnostic procedures, (2.) monitoring, and (3.) pharmaceuticals. The calculation is based on a remuneration scheme in the statutory health insurance system. In treatment-naive noncirrhotic patients, the average cost is 41 766 (sic)/SVR for the treatment with SOF/LDV calculated (PTV/r/ OMV+ DSV: 53 129 (sic)/SVR). In treatment-naive cirrhotic patients, costs were 60 323 (sic)/SVR (SOF/LDV + RBV) and 80 604 (sic)/SVR (PTV/r/OMV+ DSV+ RBV). Treatment-experienced genotype 1 patients had average costs of 60 366 (sic)/SVR for SOF/LDV treatment as well as 53 134 (sic)/SVR for PTV/r/OMV+ DSV +/- RBV treatment (cirrhotic patients: 62 208 (sic)/SVR for SOF/LDV+ RBV; 80 824 (sic)/SVR for PTV/r/OMV + DSV+ RBV). The average treatment costs per SVR in treatment-naive genotype 1 patients are comparable to previous standard of care treatments and lower in treatment-experienced patients. In other genotypes, treatment costs and costs per cure are significantly higher compared to previous standard of care. However, long-term modelling studies show that new regimens are cost-effective.